# GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

> **NCT07021209** · PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 30 (estimated)

## Conditions studied

- Neurological Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** GT719 Injection

## Key facts

- **NCT ID:** NCT07021209
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2028-01-13
- **Final completion:** 2028-01-13
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021209, "GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07021209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*